Business
Magenta Therapeutics to Present New Clinical and Preclinical Data at American Society of Hematology (ASH) Annual Meeting
-- First clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of stem cells in 11 of 12 healthy volunteers within
About this update from Dianthus Therapeutics, Inc.
[{"type":"text","content":"\n-- First clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of stem cells in 11 of 12 healthy volunteers within hours; updated data including apheresis collection to be presented at ASH –\n\n\n-- Single dose of CD117-ADC demonstrates first-ever successful gene therapy transplant in primates without chemotherapy conditioning, in collaboration with NIH --\n\n\n-- Additional presentations from across the pipeline will showcase progress in autoimmune diseases, blood cancers and genetic diseases –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nMagenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today announced that new data from across its pipeline will be presented at the 61st Annual Meeting of the American Society of Hematology (ASH).\n\n\n“The breadth of new results we are presenting at ASH illustrates our progress toward enabling patients with autoimmune diseases, blood cancers and genetic diseases to benefit from curative stem cell transplant. In today’s abstracts we are particularly excited to share the first clinical data from our MGTA-145 program, which we are developing as a first-line stem cell mobilization drug. The data in the abstract show that MGTA-145 in combination with plerixafor was well-tolerated and successfully mobilized the target stem cell dose in 11 of 12 subjects within hours of administration. At ASH we anticipate sharing initial data from mobilization and collection of the target number of cells in subjects in a single-day procedure for the first time,” said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. “We are also pleased to show groundbreaking data from our most advanced patient preparation program, CD117-ADC, in today’s abstract. These data, which will be shared in an oral presentation at ASH by Dr. John Tisdale of the National Institutes of Health, show the first-ever successful transplant in non-human primates using a targeted, single-agent antibody-drug conjugate, without the use of chemotherapy or radiation. These data provide additional validation for both our CD117-ADC program as well as our entire ADC-based patient preparation portfolio.”\n\n\nFirst Data from MGTA-145 Clinical Program\n\n\nTitle: Rapid a...